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Abstract
Nitric oxide is a signalling molecule with an extensive range of functions in both
health and disease. Discovered in the 1980s through work that earned the Nobel
prize, nitric oxide is an essential factor in regulating cardiovascular, immune, neurological
and haematological function in normal homeostasis and in response to infection. Early
work implicated exaggerated nitric oxide synthesis as a potentially important driver of
septic shock; however, attempts to modulate production through global inhibition of
nitric oxide synthase were associated with increased mortality. Subsequent work has
shown that regulation of nitric oxide production is determined by numerous factors
including substrate and co-factor availability and expression of endogenous regulators. In
sepsis, nitric oxide synthesis is dysregulated with exaggerated production leading to
cardiovascular dysfunction, bioenergetic failure and cellular toxicity whilst at the same
time impaired microvascular function may be driven in part by reduced nitric oxide
synthesis by the endothelium. This bench to bedside review summarises our current
understanding of the ways in which nitric oxide production is regulated on a tissue and
cellular level before discussing progress in translating these observations into novel
therapeutic strategies for patients with sepsis.
Keywords: Nitric oxide, Sepsis, Septic Shock, Arginine, Asymmetric dimethylarginine,
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Background
The discovery of nitric oxide
Nitric oxide (NO) was the first endogenous gaseous signalling molecule to be discov-
ered and was the product of work undertaken over an extended period by many scien-
tists tackling questions about vascular and immune cell function. The culmination of
this work included the demonstration by Robert Furchgott that rapid reductions in
smooth muscle tone were driven by production of an endothelial cell dependent medi-
ator. Described initially as endothelial derived relaxing factor (EDRF) [1], Salvador
Moncada went on to demonstrate that EDRF was in fact identical to NO [2]. In paral-
lel, the discovery by Ferid Murad that nitric oxide (NO) was a potent activator of sol-
uble guanylate cyclase [3] ultimately led to the confirmation by Louis Ignarro that NO
was the second messenger molecule responsible for reducing smooth muscle tone
through this mechanism. This work secured Furchgott, Ignarro and Murad the Nobel
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prize for physiology or medicine in 1998 [4], an award that was built on a body of work
going back many years across many disciplines.
NO synthesis and actions
NO is synthesised by nitric oxide synthase (NOS) from the guanidino group of arginine
through oxygen and NADPH dependent oxidation producing NO, with citrulline as a
by-product. Three isoforms of nitric oxide synthase regulate the production and vary in
their tissue distributions. Neuronal NOS (nNOS) is predominantly found in the ner-
vous and enteric systems but also in vascular smooth muscle [5] and cardiac myocytes
[6]. Endothelial NOS (eNOS) is found predominantly in the endothelium and cardiac
mycoytes [7]. The inducible isoform (iNOS) is widely expressed in response to inflam-
matory stress although is found constitutively at low levels in some tissues.
The actions of NO can be broadly divided into direct and indirect. Classically, NO
acts as a second messenger through direct activation of soluble guanylate cyclase (sGC)
resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) and re-
duced vascular tone. In addition to the direct action on sGC, NO directly binds to
heme moieties on a range of proteins and leads to a number of processes including
modulation of the mitochondrial electron transport chain at the level of complex IV
and inhibition of cytochrome P450–mediated metabolism.
Indirectly, NO mediates its effects through its role as a free radical. NO rapidly inter-
acts with other free radicals such as superoxide to form secondary metabolites such as
peroxynitrite (ONOO−). Through similar reactions it can intercept lipid oxidation
products (peroxy radicals) and act as chain-breaking antioxidant [8, 9].
The impact of the NO production in sepsis is extensive; however, the literature and
in some respects its interpretation are conflicting. A detailed review of the function of
NO is beyond the scope of this review; however, NO is essential to the maintenance of
normal cardiovascular and immune responses to infection. It has diverse effects includ-
ing maintenance of microvascular function, regulation of platelet aggregation and
leukocyte activity, adhesion and transport [10]. Similarly, NO is directly toxic to most
bacteria and has free radical scavenging action which reduces tissue injury and bioener-
getic dysfunction. However, in sepsis and septic shock, these processes become dysreg-
ulated to variable degrees. Exaggerated NO production has been implicated in the
development of macrovascular compromise [11], myocardial dysfunction [12], reduced
responsiveness to adrenergic stimuli [13, 14], direct cellular toxicity and bioenergetic
failure [15, 16]. Conversely, impaired local NO production in the endothelium has been
cited as a cause of the microvascular dysfunction and impaired regional perfusion seen
in septic shock.
Regulation of NO synthesis
The balance of harmful and beneficial effects is determined by a series of regulatory
processes that determine the site and degree of NO synthesis that arises in response to
an inflammatory stimulus.
The active isoforms of NOS are homodimers and depend upon a range of co-factors
for their activity. Dimerisation is essential for activation and leads to the sequestration
of iron and creation of binding sites for arginine and the essential cofactor
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tetrahydrobiopterin (BH4). In addition, dimerisation facilitates electron transfer be-
tween two key domains linked by a calmodulin binding motif. In eNOS and nNOS, the
binding of calmodulin to the NOS homodimer is calcium dependent. Conversely, cal-
modulin is tightly bound to iNOS and therefore displays calcium independent activa-
tion. Enzymatic activity also depends upon, haem, flavin mononucleotide (FMN) and
flavin adenine dinucleotide (FAD) availability as well as oxygen and NADPH as co-
substrates (Fig. 1).
Differential expression of the NOS isoforms within the cell or in tissues also influ-
ences NO synthesis. eNOS is commonly found bound to caveolin, a specialised anchor-
ing protein within the caveolae of the endothelial cell membrane [17] which may itself
regulate NO production [18]. This conformation has been implicated in the develop-
ment of reduced NO synthesis in the septic microvasculature. In myocytes, the three
NOS isoforms are differentially distributed with eNOS predominantly found in endo-
thelium, nNOS in the presynaptic nerves and both found in different portions of the
sarcoplasmic reticulum. iNOS by contrast, when induced by pro-inflammatory stress is
most commonly found in the cytoplasm where it generates a two or three log fold
higher increases in NO synthesis compared to the constitutive isoforms.
Therapeutic modulation of NO in sepsis
In the years following its discovery came a burgeoning recognition that NO played an
important role in the development of the vasoplegia and hypotension that is the
Fig. 1 Nitric oxide synthase (NOS) cofactors and activity. NOS enzymes function as homodimers within
subunits structurally supported by a Zinc ion (Zn2+). Following sequestration of iron, the binding site for
arginine is expressed. Electron transfer also depends on flavin mononucleotide (FMN) and flavin adenine
dinucleotide (FAD) availability and the binding of calmodulin (CaM) which is calcium dependent for eNOS
and nNOS and independent for iNOS. NADPH, oxygen and tetrahydrobiopterin (BH4) are essential cofactors
for the synthesis of nitric oxide
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hallmark of septic shock. This led first to small scale studies of inhibition of sGC activ-
ity by methylene blue [19, 20], and subsequently, clinical trials of the non-specific small
molecule inhibitor of all three NOS isoforms, L-NMMA. Phase II results [21] showed
promise as L-NMMA demonstrated improved systemic vascular resistance and blood
pressure in patients with septic shock. However, a phase III trial was terminated early
due to excess mortality in the treatment group [22]. Questions regarding dose selection,
blood pressure management and treatment strategy meant that interest in the area was
not extinguished, and subsequent work has recognised the plethora of roles that NO
has in regulating organ function in both health and disease.
In recent years, potential approaches to modulating NO production in sepsis have
been developed targeting pathways beyond direct NOS inhibition. The remainder of
this review will focus on a selection of these strategies which include modulating en-
dogenous regulators of NOS activity, NO scavenging or donation and optimising sub-
strate availability.
Nitric oxide inhibition
Endogenous regulators of NOS activity
Tetrahydrobiopterin (BH4) is an essential cofactor for NOS-mediated NO synthesis
through facilitation of electron transfer to L-arginine. Reduced BH4 bioavailability re-
sults in the diversion of electron flow to molecular oxygen and production of free rad-
ical superoxide rather than N O[23], a process also known as NOS uncoupling.
Reduced BH4 bioavailability has been implicated in the development of chronic cardio-
vascular diseases through this mechanism.
Whilst in sepsis, pro-inflammatory stress has been shown to increase production of
BH4 [24], coexistent oxidative stress and reactive oxygen species cause conversion of
BH4 to BH2. In addition to depleting BH4 scores, BH2 binds to NOS with equal affin-
ity but promotes the uncoupling process [25] thereby reducing NO production. In mal-
aria, increasing severity of disease is associated with reduced BH4 levels and BH4:BH2
ratio [26] and has been proposed as a driver of microcirculatory dysfunction in this
population.
Supplementation of a BH4 analogue appears to reduce haemodynamic impairment,
organ dysfunction and improve survival in rat models of acute inflammation and sepsis
[27–29]. In an ovine model of septic shock secondary to faecal peritonitis, supplemental
tetrahydrobiopterin therapy was associated with preservation of the sublingual micro-
circulation, reduced cardiovascular compromise and severity of lung and renal injury
[30]. Furthermore, In animal models, ascorbate supplementation has been shown to re-
store capillary blood flow and eNOS activity in a BH4 dependent manner [31]. This has
been postulated as one of the mechanisms underlying the potential benefits of Vitamin
C supplementation in sepsis.
A further example of potential therapeutic approaches includes increasing the expres-
sion of endogenous inhibitors of NO synthesis. Derived from the methylation of arginine
residues by the Protein Arginine Methyl Transferases (PRMTs), the methylarginines have
an unusual physiological role in regulating the synthesis of NO. The three methylarginines
are asymmetric dimethylarginine (ADMA), symmetric dimethyl arginine (SDMA) and, oc-
curring at approximately a tenth of the concentration, monomethylarginine (L-NMMA).
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The asymmetric pair, ADMA and L-NMMA, acts as equipotent competitive inhibitors of
arginine binding to the all three NOS isoforms. By contrast, SDMA has no direct action
on NOS activity. Elevated levels of both ADMA and SDMA are associated with poor out-
come in patients with sepsis; however, an increase in the ratio of ADMA to SDMA is as-
sociated with reduced mortality in patients with septic shock [32], suggesting there may
be a disconnection between the association of elevated ADMA levels and the mechanisms
responsible for dysregulated NO production.
The dominant method of methylarginine handling is enzymatic and driven by one of
the two dimethylarginine dimethylaminohydroxylases (DDAH1 and DDAH2). Approxi-
mately 80% of ADMA and L-NMMA are metabolised to dimethylarginine (DMA) and
L-citrulline by the DDAH isoforms, with the remaining 20% excreted by the kidney
[33] (Fig. 2).
In addition to expression in the vasculature [34], DDAH1 is readily identified in the
liver, kidney, brain, skeletal muscle and pancreas [35]. Small amounts of DDAH1 have
also been found in the pulmonary vasculature [36] and in placental [37] tissues. The
tissue distribution of DDAH2 differs markedly from that of DDAH1. Whilst both iso-
forms are found in blood vessels, liver and kidney, DDAH2 predominates in the pla-
centa and is not found in the central nervous system. It is also the only isoform found
in cardiomyocytes and in immune tissues [34, 35, 38]. This has led to the suggestion it
may play an important role in the response to inflammatory or immune mediated
conditions.
Fig. 2 Methylarginine-mediated nitric oxide synthase inhibition. Representative image of the synthesis and
regulation of ADMA. Protein Arginine Methyl Transferases (PRMT) catalyse the methylation of arginine
containing protein residues to ADMA and SDMA which are released upon proteolysis. ADMA and SDMA are
transported via the y+ cationic amino acid transporter into and out of the circulation. ADMA is metabolised
by the two isoforms of dimethylarginine dimethylaminohydrolase (DDAH) in a wide range of tissues. ADMA
acts intracellularly to inhibit nitric oxide synthase (NOS). ADMA is largely metabolised by DDAH to dimethylamine
(DMA), a small amount is cleared unchanged through the kidney. nb. L-NMMA (monomethylarginine) is
considered to have the same synthetic pathway, activity, metabolism and clearance as ADMA but is present in
only 10% of the concentration
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In rodent lipopolysaccharide (LPS) and polymicrobial models, both genetic and thera-
peutic inhibition of DDAH1, has been shown to offer improved survival [39]. In
addition, DDAH1 inhibitor therapy was found to reduce the severity of hypotension
and requirement for noradrenaline to maintain normal blood pressure. These effects
still occurred when treatment was delayed until after the onset of shock symptoms.
Furthermore, DDAH1 inhibition was shown to improve indices of renal and hepatic
function, preserve microvascular flow and improve survival without any effect on im-
mune cell function [39]. This favourable balance of improved vascular function without
the deleterious impacts on the cardiac or immune system has led to DDAH1 inhibition
being postulated as a potential therapeutic approach in septic shock.
Nitric oxide scavenging
The recognition that NO has essential functions in sepsis and that global inhibition of
NO synthesis could have harmful effects, led to the hypothesis that scavenging excess
NO might prove an effective therapeutic strategy [40]. One of these approaches was the
development of pyridoxylated haemoglobin polyoxyethylene (PHP), which was origin-
ally developed as a candidate oxygen delivery substitute. PHP is pyridoxylated to re-
move its oxygen carrying capacity and then combined with polyoxyethylene to increase
the apparent molecular weight of the compound. The resulting product has a high af-
finity for NO which it rapidly oxidises to the more stable nitrate as well as reducing
peroxynitrite concentrations and regulating the redox state of the cell [41].
Preclinical ovine models of sepsis demonstrated that PHP improved systemic vascular
resistance [42] and that treatment was not associated with impaired tissue perfusion.
This led to a phase II study in of 62 patients with septic shock [43]. In this study, those
treated with PHP displayed trends towards reduced requirements for vasopressors and
ventilatory support. This was followed by the phase III PHOENIX study [44], which re-
cruited 377 patients. The study showed no survival benefit following PHP therapy at
28 days but evidence of increased mortality in patients with a SOFA score of > 13 on
inclusion. Despite this, the previously observed improvements in systemic haemo-
dynamics persisted, with survivors displaying reduced duration of vasopressor therapy.
The authors concluded that regional variation in NO synthesis in the microcirculation
could have been exacerbated in the PHP treated patients thereby worsening organ per-
fusion and accounting for the worse outcomes observed. This coupled with the inability
to identify which patients had more substantially elevated systemic NO levels based on
noradrenaline requirement meant that selecting patients that might benefit from this
approach based on clinical indices was not possible.
Increasing nitric oxide bioavailability
Substrate bioavailability
Arginine is the substrate for NOS enzymes and its availability is a dominant factor in
the regulation of NO production. Whilst most bioavailable arginine is derived from the
diet, the intracellular concentrations are governed by a range of processes including
transmembrane transport, enzymatic synthesis and metabolism.
In sepsis, arginine becomes a conditionally essential amino acid with reduced bio-
availability resulting from a variety of factors. Exaggerated protein turnover leads to an
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increase in stored arginine release however in patients with sepsis, reduced dietary in-
take of arginine and citrulline [45, 46] is coupled with increased turnover by NOS and
arginase enzymes [47]. This coupled with reduced de novo synthesis at the tissue level
in organ failure [48] means that circulating arginine concentrations are substantially re-
duced regardless of the infectious cause [49–51] with direct consequences for the pro-
duction of NO and the microcirculation [52]
Extensive investigation has been undertaken exploring the potential role of exogenous
arginine supplementation in sepsis. A number of animal models have produced promis-
ing results with a murine [52] and pretreatment porcine inflammatory model [53]
showing improved microvascular function and organ perfusion mediated by increased
NO production. In healthy volunteers, arginine supplementation is well tolerated at
doses less than 8g/day; however, supplementation at doses above this was associated
with gastrointestinal side effects [54]. In patients with critical illness, arginine supple-
mentation has not consistently demonstrated clinically relevant improvements in out-
come. There is some trial evidence suggesting supplementing arginine in addition to
other nutrients may result in a reduced hospital length of stay [55] or improved organ
function [56]. Preiser et al. [57] successfully increased plasma arginine concentrations
via enteral supplementation in a small randomised controlled trial of a mixed ICU
population. Whilst this was associated with some signal of increased arginase activity,
no increase in plasma markers of NO production was detected. In a subsequent rando-
mised trial of 597 critically ill patients, an immunonutrition approach including supple-
mentation of arginine as well as glutamine and omega-3 was not associated with
improved clinical outcomes [58]. A further study of arginine containing enteral immu-
nonutrition versus parenteral therapy was stopped after an interim analysis suggested
an excess mortality in patients receiving enteral supplementation [59]. This has led to
the recommendation in the surviving sepsis guidelines that arginine supplementation is
not used to treat patients with sepsis [60].
In addition to dietary uptake, arginine can be synthesised through the conversion of
citrulline by a pair of enzymes that are found in the cytosol, argininosuccinate synthe-
tase (ASS) and argininosuccinate lyase (ASL) [61] (Fig. 3). The majority of bioavailable
citrulline is synthesised by enterocytes with some derived from the diet [62] and a small
proportion synthesised in the kidney, liver and enterocytes from ornithine by ornithine
transcarbamoylase [63]. Citrulline bioavailability is also reduced in sepsis. Observed in
patient populations to be associated with increased mortality [64], a low citrulline con-
centration is likely multifactorial. In addition to reduced dietary intake, reduced uptake
of the citrulline precursor glutamine from the gut may play a role [65]. Compensatory
increases in the expression of ornithine transcarbamoylase which synthesises citrulline
from ornithine in the kidney may mitigate this effect to some degree [66].
A number of cell types use citrulline conversion by ASS and ASL to generate en-
dogenous arginine. These include vascular smooth muscle [67], macrophages [68],
neural cells [69] and endothelial cells [70, 71]. Importantly, in endothelial cells, ASS
and ASL co-locate with eNOS and play an important role in regulating endogenous
NO synthesis [72].
In sepsis, ASS expression is elevated in both the vasculature and immune cell popula-
tions, possibly in order to facilitate local NO production by iNOS [73, 74]. In animal
models, heterozygote and tissue specific knockout of ASS are associated with worse
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outcomes due to reduced immune cell NO synthesis [75]. Supplementation with re-
combinant ASS mitigates the lethal effects of LPS in animal models although the mech-
anism of efficacy may also be related to direct binding to Gram negative bacteria
reducing organism pathogenicity rather than the production of increased arginine [74].
With the similar aim of augmenting arginine and subsequent NO bioavailability and
with some evidence from animal models [52], citrulline supplementation has also been
proposed as a possible treatment strategy in sepsis. Whilst there is some evidence of as-
sociation between low citrulline concentrations and the development of ARDS [46] and
gut mucosal integrity in patients with sepsis [76], there is no prospective evidence to
recommend citrulline supplementation at this stage.
The isoforms of the arginase enzymes degrade arginine to ornithine and urea render-
ing it an important regulator substrate availability and therefore of NO synthesis in the
cell (Fig. 3). The arginase isoforms have differing tissue distributions, with arginase 1
expressed in endothelial cells, immune cells and the liver. Arginase 2 is also found in
the endothelium [77] and immune cells [78] but is also detected in the kidney, brain
and small intestine.
The expression of arginase isoforms during sepsis is a dynamic process that points to
a role in regulating the initiation and resolution of inflammation [79–81] by limiting ar-
ginine availability. After an acute inflammatory stress, arginase induction typically arises
some hours after peak iNOS induction [45]. This is responsible in part for the down-
regulation of NO synthesis and is best characterised in immune cells where it defines
the transition of the macrophage from the pro-inflammatory M1 to the restorative M2
phenotype where arginase mediates the synthesis of proline and polyamines crucial to
the process of wound healing [82].
Arginase 1 knockout immune cells and mice deficient in arginase 1 in endothelial
and haematopoietic cells are prone to exaggerated NO synthesis in LPS models of in-
flammation with an associated microvascular dysfunction seen in murine models [83].
In patients, limited data suggests that levels of the enzyme in the circulation are
Fig. 3 Arginine bioavailability. Arginine (ARG) is transported into the cell via cationic amino acid transporters
and is converted to citrulline (Cit) and NO. Citrulline derived from a number of sources including diet can be
converted to arginine by argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL) increasing the
available intracellular arginine. Arginase (ARG) metabolises arginine to ornithine (Orn) and urea (Ur)
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elevated in sepsis but is not directly related to clinical indices of illness severity [84]. Al-
though no therapeutic evaluation of arginase modulation is underway, the role of the
enzymes in regulating systemic and local arginine concentrations is undoubtedly im-
portant and further understanding of the balance between NOS and arginase expres-
sion may yield novel therapeutic approaches.
Targeting microcirculatory dysfunction
The wide recognition of the importance of NO in maintaining the microcirculation, com-
bined with the negative outcomes of trials of NOS inhibition has also led to suggestions
that rather than reducing synthesis of NO, attention should focus on the use of NO do-
nors to improve microvascular function, reduce shunting and optimise tissue perfusion in
septic shock. Two distinct approaches have been proposed. The first involves optimising
eNOS activity within the vascular endothelium which, as described above, is known to be
impaired in sepsis due to the uncoupling of NO production due in part to reduced BH4
availability, lack of availability of substrate and elevated oxidative stress.
The alternative therapeutic strategy is to deliver exogenous compounds which can re-
lease NO at the microcirculatory level in order to optimise small vessel function. There
are a number of proposed functions of the microcirculation that could be improved
through NO modulation which include smooth muscle relaxation, reduced platelet ag-
gregation and microthrombus formation and reduced endothelial leak and interstitial
oedema. In addition, there is evidence that inorganic nitrites may offer some protection
from ischaemia reperfusion injury and have a cardioprotective effect through a range of
actions on mitochondrial and cellular function [85, 86].
This approach was tested in a small study of 8 patients as early as 2002 with nitrogly-
cerin infusion which led to reported improvements in the sublingual microcirculation
[87] although a subsequent randomised controlled trial published in 2010 randomised
70 patients to receive nitroglycerin infusion or placebo and found that this was not as-
sociated with improved microvascular flow in any category of vessel or interestingly on
systemic haemodynamics, suggesting that it may not have been having the desired
pharmacodynamic effect [88]. One potential reason for this could be the failure to ef-
fectively convert nitroglycerin to NO in vivo due to dysfunction of aldehyde dehydro-
genase type 2 in capacitance vessels, which may not function effectively in patients with
sepsis and leads to reduced nitroglycerin bioactivation [89]. This however remains only
one endogenous route of activation [90] and therefore may not entirely explain this ap-
parent result.
Based on a similar methodological approach, the direct administration of NO via an
inhaled route has recently been trialled in patients with sepsis [91]. In a randomised
trial of 50 patients, direct NO administration was able to increase circulating nitrite
levels consistent with the hypothesis that pulmonary delivery of NO could lead to in-
creased systemic availability; however, no impact on sublingual microvascular or organ
function was detected.
Conclusions
Extensive research has led to the recognition that NO synthesis is regulated by a range
of mechanisms which determine the production and actions of NO. Substrate and co-
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factor availability all contribute to NOS activity, which also determined on a tissue level
by protein expression, cellular localisation and the presence of endogenous regulators.
In the last decade therapeutic research into the modulation of NO in critical illness
has taken on a Janusian quality as it explores the competing challenges of overproduc-
tion of NO in some systems and impaired synthesis in others. Exaggerated NO produc-
tion is responsible for cardiac, macrovascular and cellular dysfunction; however,
microvascular function due to reduced eNOS activity and NO synthesis also appears to
play an important role in outcome. The development of novel treatments in this area
must mitigate the pathological consequences of at least one of these without exacerbat-
ing the other or impairing the essential physiological NO synthesis that is core to the
response to infection. This challenge must be addressed if an improved understanding
of the mechanistic role of NO in sepsis can be translated into therapies that improve
outcomes for patients.
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